Genetic variations influence everolimus benefit in advanced breast cancer Healio Women with hormone receptor-positive, HER-2–negative advanced breast cancer who had minimal genetic variations in PI3K, FGFR or CCND1 derived the most benefit from everolimus therapy, according to study results presented at the Breast Cancer ... |
